Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome – a retrospective analysis
- 6 March 2012
- journal article
- research article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 28 (10) , 823-826
Abstract
Background: Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome. We analyzed the effect of 6 months of therapy with these drugs on body weight and glucose tolerance. Results: This was a retrospective analysis of polycystic ovarian syndrome (PCOS) cases on treatment. There were 88 patients with PCOS-42 were on metformin 1 g daily and 46 were taking spironolactone 50–75 mg daily. 21 of 42 had abnormal glucose tolerance (AGT) in the metformin group and 13 of 46 had AGT in the spironolactone group. Patients on metformin reported a greater reduction in body weight, whereas there was no change in body weight with spironolactone therapy (67.6–63.7 versus 59.6–59.2 kg). There was a significant reduction in the 1 and 2 h glucose and insulin levels with metformin therapy in those with AGT. However, fasting glucose increased in those with normal glucose tolerance. There was no change in either body weight or insulin levels with spironolactone. But, there was a significant reduction in both the 0 and 2 h glucose with spironolactone also in those with AGT. Conclusion: Spironolactone and metformin had similar effect in reducing the glucose levels in PCOS patients with AGT. PCOS patients with normal glucose tolerance had higher fasting plasma glucose at the end of 6 months of metformin therapy inspite of weight reduction.Keywords
This publication has 20 references indexed in Scilit:
- Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive ReviewEndocrine Reviews, 2008
- Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implicationsExpert Reviews in Molecular Medicine, 2008
- Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistanceGynecological Endocrinology, 2007
- How prevalent is metabolic syndrome in women with polycystic ovary syndrome?Nature Clinical Practice Endocrinology & Metabolism, 2006
- Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profileJournal of Endocrinological Investigation, 2005
- Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled StudyThe Journal of Clinical Endocrinology & Metabolism, 2004
- Insulin-Lowering Agents in the Management of Polycystic Ovary SyndromeEndocrine Reviews, 2003
- Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic PopulationDiabetes Care, 2003
- Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancyMetabolism, 1994
- Relationship of Androgenic Activity to Body Fat Topography, Fat Cell Morphology, and Metabolic Aberrations in Premenopausal Women*The Journal of Clinical Endocrinology & Metabolism, 1983